Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05600608
Other study ID # 21HH6980
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2022
Est. completion date December 20, 2023

Study information

Verified date October 2022
Source Imperial College London
Contact Anuja T Mitra, MBBS, BSc
Phone 07545980633
Email anuja.mitra06@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nearly 10,000 people die each year in the United Kingdom from cancer of the lower gullet and stomach, known as known as oesophago- gastric adenocarcinoma (OGC). OGC is detected late as symptoms are non- specific and often mistaken for common problems such as heartburn. This translates to fewer than 2 in every 10 patients diagnosed with OGC living longer than 5 years. The breath of people with OGC is enriched with volatile chemicals (VOCs) that indicate cancer. When measured in a breath test, it detects OAC 80 out of 100 times. Whilst encouraging, there is scope to improve the detection rate by giving patients a stimulant drink that amplifies the production of tumour specific VOCs only, to increase their detection in the breath test. The goal of this observational study is to produce an enhanced second-generation breath test with superior ability to detect OGC through augmentation of breath. This will improve long term survival from cancer using an entirely non- invasive test. All participants (cancer and control participants) will consume an oral stimulant drink (OSD) and provide breath samples pre and post consumption of the drink at set time points (maximum 2 hours after consumption of the drink). The investigators will compare the breath VOCs from both groups, before and after consumption of the OSD to see if the OSD has a desired augmentation effect and can improve the accuracy of the OGC breath test. With this second-generation breath test, participants with vague symptoms can undergo a quick, non- invasive test, have samples analysed in a safe and accurate manner and be subsequently stratified based on their risk of having OGC, leading to earlier disease detection and improved clinical outcomes.


Description:

Introduction: Early detection of oesophago- gastric adenocarcinoma (OGC) with improved diagnostics is essential to reduce the burden of this aggressive cancer. The breath of people with OAC is enriched with volatile organic compounds (VOC). A breath test based on these VOCs has an 80% sensitivity and 81% specificity of detecting OAC. The diagnostic accuracy may be further improved by using an exogenous stimulant that amplifies the production of OGC specific VOCs. This strategy is known as 'augmentation'. It is possible to compare intra- subject breath (pre and post stimulant) and use the fold increase in VOCs to detect cancer. This is the investigator's novel approach to improving breath test sensitivity and early OGC detection. The biology of the OGC VOCs must be first understood to selectively augment their production. Background: The OGC lipidome is enriched with phospholipids that are vulnerable to degradation via lipid peroxidation, which is a principal mechanism for endogenous VOC production. Prokaryotic lipids in the OGC microbiome are also vulnerable to peroxidation. Putative drivers of lipid peroxidation are higher in tumour environment. This suggests OGC lipids and/ or prokaryotic lipids may be source compounds for diagnostic VOCs and this mechanism may be augmented. Aim: to augment the production of OGC VOCs to improve the diagnostic performance of the breath test. Proposal: 1) A lipidomics study of the onco- microbial lipidome using bespoke mass spectrometry with phenotyping of the corresponding VOCs will identify source lipids that generate diagnostic VOCs, 2) data driven stable isotope experiments to select an augmentation model based on the degradation kinetics of the source lipid in vivo and 3) translating the science to clinic with a study of the augmented breath test in participants with OGC. Translation of the novel scientific data generated to clinic presents a real opportunity to improve clinical outcomes in people with OGC.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 20, 2023
Est. primary completion date April 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 90 Years
Eligibility Inclusion Criteria: - Participants should be over 18 years old and up to the maximal age of 90 years , AND: - Have a confirmed histological diagnosis of oesophageal OR gastric adenocarcinoma at Imperial NHS Healthcare Trust, AND - Will undergo am oesophagogastroscopy (OGD) as part of their routine clinical care, OR: - Will undergo surgical resection of their oesophageal or gastric cancer as part of their routine clinical care OR - Any patient with non- cancerous upper gastrointestinal (benign) problem who will have an OGD OR surgery as part of their routine clinical care at Imperial NHS Trust Exclusion Criteria: - Participant that lacks capacity or is unable to provide informed consent - Any participant below 18 years of age or over 90 years of age - Participants with allergies to any aspect of the metabolic drink - Participants who have had previous OG surgical resection

Study Design


Intervention

Dietary Supplement:
Oral Stimulant Drink
please see description of the drink in the arm/ group section

Locations

Country Name City State
United Kingdom Volatile Biomarker Group, Commonwealth Building, Hammersmith Hospital, Imperial College London London

Sponsors (4)

Lead Sponsor Collaborator
Anuja Mitra British Association of Surgical Oncology, British Medical Research Council, The Royal College of Surgeons of England

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Antonowicz S, Bodai Z, Wiggins T, Markar SR, Boshier PR, Goh YM, Adam ME, Lu H, Kudo H, Rosini F, Goldin R, Moralli D, Green CM, Peters CJ, Habib N, Gabra H, Fitzgerald RC, Takats Z, Hanna GB. Endogenous aldehyde accumulation generates genotoxicity and ex — View Citation

Markar SR, Wiggins T, Antonowicz S, Chin ST, Romano A, Nikolic K, Evans B, Cunningham D, Mughal M, Lagergren J, Hanna GB. Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer. JAMA Oncol. 2018 Jul 1;4(7):970-976. do — View Citation

Mitra A, Choi S, Boshier PR, Razumovskaya-Hough A, Belluomo I, Spanel P, Hanna GB. The Human Skin Volatolome: A Systematic Review of Untargeted Mass Spectrometry Analysis. Metabolites. 2022 Sep 1;12(9). pii: 824. doi: 10.3390/metabo12090824. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To establish a second- generation augmented breath test with improved diagnostic accuracy for the detection of OG adenocarcinoma. This breath test will utilise serial breath sampling following the ingestion of an augmentation solution (OSD). Breath samples will be taken pre and post consumption of the OSD and fold changes in the VOCs will be calculated. The entire process of breath sampling is non- invasive. 12 months
Primary To determine the diagnostic accuracy of the augmented exhaled breath test, in the prediction of oesophago-gastric cancer (OGC). The investigators will generate an untargeted VOC breath model following exhaled VOC augmentation. 12 months
Secondary To comprehensively characterise the tissue lipid input and lipidomic reprogramming in oesophagaeal and gastric adenocarcinoma in comparison to healthy non- cancer tissues. Liquid chromatography mass spectrometry (LCMS) comprehensive lipidomic OGC tissue profiling will be performed by the investigators to generate a lipid map in healthy and cancer tissues. deadline December 2022
Secondary To identify the mechanistic pathways and origins of the production of breath Volatile compounds by investigating the tumour lipidome. The investigators will perform a range of in silico, in vitro and ex vivo experiments that determine the mechanisms and kinetics of lipid to VOC generation 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Recruiting NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2